TARA | Protara Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8100 - 1.9110
52 Week Range	1.0400 - 5.24
Beta	2.06
Implied Volatility	295.01%
IV Rank	100.00%
Day's Volume	77,775
Average Volume	173,862
Shares Outstanding	20,629,800
Market Cap	38,577,726
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-10-22

Valuation
Profitability
Growth
Health
P/E Ratio	-0.62
Forward P/E Ratio	N/A
EPS	-3.03
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	26
Country	USA
Website	TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

TARA's peers: GTBP, MTEM, ONCT, PSTV, RANI, SVRA, SYBX, VCNX, MNPR, MIRO, SRZN, IKNA, XLO, SRRK, VACC, MTCR, MGTA, TCON, STSA, LYRA, TRVI, SQZ, URGN, VINC, VIRX

*Chart delayed

Analyzing fundamentals for TARA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TARA Fundamentals page.

Watching at TARA technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on TARA Technicals page.